Loading…
Employees: 1,465
Size Hefei Lifeon Pharmaceutical (003020.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $520M, the 3773rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.20 on 6 Nov 2026.
Performance Over six months the shares fell 19.8%, against -20.0% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 0.6% over the last twelve months (peer median +11.6%); the operating margin is 10.0% (peer median 8.7%).
Valuation It trades at 19.5× forward earnings against a peer median of 14.3× (2nd most expensive of 6).
Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.46B | CN¥1.54B | CN¥1.50B | CN¥1.88B | CN¥2.56B |
| Revenue growth | — | +2% | -20% | -27% | — |
| Gross profit | CN¥1.00B | CN¥955M | CN¥1.00B | CN¥944M | CN¥932M |
| EBITDA | n/a | CN¥228M | CN¥238M | CN¥254M | CN¥233M |
| Net income | CN¥153M | CN¥165M | CN¥161M | CN¥227M | CN¥209M |
| Free cash flow | -CN¥439M | CN¥119M | CN¥48.9M | CN¥132M | -CN¥8.40M |
| Capital expenditure | CN¥105M | CN¥118M | CN¥154M | CN¥198M | CN¥246M |
| Total debt | CN¥132M | CN¥114M | CN¥128M | CN¥109M | CN¥254M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 003020.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -9.3% | 10th lowest of 21 |
| 6-month return | -19.8% | -20.0% | 11th highest of 21 |
| Distance from 52-week high | -43.7% | -37.2% | 10th lowest of 21 |
| Revenue growth (TTM) | -0.6% | +11.6% | 6th lowest of 20 |
| Operating margin | 10.0% | 8.7% | 10th highest of 19 |
| Forward P/E | 19.5× | 14.3× | 2nd most expensive of 6 |
| ROIC minus cost of capital | +4.4 pp | -2.8 pp | 7th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 19.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | n/a | 47.1% | -12.3% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 14.3× | 1.7% | +14.5% |